DEFINE - a Randomized, Open-Label Trial of the Inhaled Galectin-3 Inhibitor GB0139 in Hospitalized Patients with Moderate-to-Severe COVID-19

被引：0
|
作者：
Gaughan, E. [1 ]
Sethi, T. [2 ]
Quinn, T. [1 ]
Hirnani, N. [1 ]
Mills, A. [3 ]
Bruce, A. M. [1 ]
Mackinnon, A. [2 ]
Aslanis, V. [2 ]
Li, F. [1 ]
O'Connor, R. [1 ]
Dear, J. [4 ]
Akram, A. R. [1 ]
Koch, O. [5 ]
Wang-Jairaj, J. [2 ]
Slack, R. J. [2 ]
Gravelle, L. [2 ]
Lindmark, B. [2 ]
Dhaliwal, K. [1 ]
机构：
[1] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[2] Galecto Inc, Copenhagen, Denmark
[3] Explorist, Belfast, Antrim, North Ireland
[4] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[5] NHS Lothian, Infect Dis Dept, Edinburgh, Midlothian, Scotland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2022年 / 205卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3127
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial
    Lingas, Guillaume
    Neant, Nadege
    Gaymard, Alexandre
    Belhadi, Drifa
    Peytavin, Gilles
    Hites, Maya
    Staub, Therese
    Greil, Richard
    Paiva, Jose-Artur
    Poissy, Julien
    Peiffer-Smadja, Nathan
    Costagliola, Dominique
    Yazdanpanah, Yazdan
    Wallet, Florent
    Gagneux-Brunon, Amandine
    Mentre, France
    Ader, Florence
    Burdet, Charles
    Guedj, Jeremie
    Bouscambert-Duchamp, Maude
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (05) : 1404 - 1412
  • [42] Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial
    Seco, Maria Pilar Ruiz
    Pardo, Jose Ramon Pano
    Schoergenhofer, Christian
    Dings, Christiane
    Lehr, Thorsten
    Herth, Felix
    Krendyukov, Andriy
    Straub, Carola
    Kappler, Martin
    Jilma, Bernd
    Fricke, Harald
    Pardo, Julian
    de Miguel, Diego
    Thiemann, Meinolf
    Bergmann, Michael
    Walczak, Henning
    Hoeger, Thomas
    ECLINICALMEDICINE, 2024, 77
  • [43] Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
    Efimov, Sergey, V
    Matsiyeuskaya, Natallia, V
    Boytsova, Olga, V
    Akhieva, Luydmila Yu
    Kuntsevich, Elena, V
    Troshina, Anastasia A.
    Kvasova, Elena, I
    Tikhonov, Anton A.
    Khomyakova, Nadezhda F.
    Harrison, Francisco
    Rossi, Jean-Francois
    Hardman, Timothy C.
    DRUGS IN CONTEXT, 2022, 11
  • [44] Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial
    Poulakou, Garyfallia
    Barakat, Maxime
    Israel, Robert J.
    Bacci, Marcelo R.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (01): : 165 - 174
  • [45] Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial
    Song, Joon-Young
    Yoon, Jin-Gu
    Seo, Yu-Bin
    Lee, Jacob
    Eom, Joong-Sik
    Lee, Jin-Soo
    Choi, Won-Suk
    Lee, Eun-Young
    Choi, Young-Ah
    Hyun, Hak-Jun
    Seong, Hye
    Noh, Ji-Yun
    Cheong, Hee-Jin
    Kim, Woo-Joo
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [46] Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study
    Karampitsakos, Theodoros
    Malakounidou, Elli
    Papaioannou, Ourania
    Dimakopoulou, Vassilina
    Zarkadi, Eirini
    Katsaras, Matthaios
    Tsiri, Panagiota
    Tsirikos, Georgios
    Oikonomou, Ioanna
    Davoulos, Christos
    Georgiopoulou, Vasiliki
    Sampsonas, Fotios
    Marangos, Markos
    Akinosoglou, Karolina
    Tzouvelekis, Argyris
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [47] Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial
    Suzuki, Manabu
    Matsunaga, Akihiro
    Miyoshi-Akiyama, Tohru
    Terada-Hirashima, Junko
    Sadamasu, Kenji
    Nagashima, Mami
    Takasaki, Jin
    Izumi, Shinyu
    Hojo, Masayuki
    Ishizaka, Yukihito
    Sugiyama, Haruhito
    DRUG DISCOVERIES AND THERAPEUTICS, 2023, 17 (05): : 304 - 311
  • [48] Diagnostic Significance of Serum Galectin-3 in Hospitalized Patients with COVID-19 A Preliminary Study
    Kusnierz-Cabala, Beata
    Maziarz, Barbara
    Dumnicka, Paulina
    Dembinski, Marcin
    Kapusta, Maria
    Bociasa-Jasik, Monika
    Winiarski, Marek
    Garlicki, Aleksander
    Grodzicki, Tomasz
    Kukla, Michal
    BIOMOLECULES, 2021, 11 (08)
  • [49] Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
    Chen, Chang
    Zhang, Yi
    Huang, Jianying
    Yin, Ping
    Cheng, Zhenshun
    Wu, Jianyuan
    Chen, Song
    Zhang, Yongxi
    Chen, Bo
    Lu, Mengxin
    Luo, Yongwen
    Ju, Lingao
    Zhang, Jingyi
    Wang, Xinghuan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [50] Galectin-3 as a Novel Biomarker for Predicting Clinical Outcomes in Hospitalized COVID-19 Patients
    Baykiz, Derya
    Emet, Samim
    Ayduk-Govdeli, Elif
    Kaytaz, Murat
    Yavuz, Mustafa L.
    Karaca-Ozer, Pelin
    Karaayvaz, Ekrem B.
    Medetalibeyoglu, Alpay
    Elitok, Ali
    Genc, Sema
    Bugra, Zehra
    Umman, Berrin
    CLINICAL LABORATORY, 2022, 68 (12) : 2483 - 2495
12345